Background: The novel coronavirus pneumonia (COVID-19), which was first detected in Wuhan City, has now became a pandemic that affecting patients around the world. Particularly, the community patient population are at high risk of infection and are facing potential failure of proper medication use during the pandemic.
Objective: To discuss community
Res Social Adm Pharm 2020. S1551-7411(20)30284-9. /
Zheng SQ, Yang L, Zhou PX, Li, et al.
Background: The performance of pharmacists in clinical services contributes to improving outcomes in patient drug therapy. In the context of streamlined resources and high health services' demand, the use of patient selection tools can screen those who would benefit more from a pharmaceutical service.
Objective: This review aims to map and
Res Social Adm Pharm 2020 Feb 21. pii: S1551-7411(19)31055-1. [Epub ahead of print] /
Sousa MDCVB, Fernandes BD, Foppa AA, et al.
Introduction: The purpose of this study was to identify trends in oncology care that allow one to forecast workforce supply and demand, the training and skills needed by the oncology pharmacist for the likely future of oncology care.
Methods: Interviews were conducted with experienced oncology pharmacists in leadership roles at 20
Journal of Oncology Pharmacy Practice 2020 April 1. [Epub ahead of print]. /
Ignoffo RJ, Knapp KK, Seung A, et al.
Lymphomas are a diverse group of hematologic malignancies that arise from either T cell, B cell or the natural killer cell lineage.
B cell lymphomas arise from gene mutations with critical functions during normal B cell development. Recent advances in the understanding of molecular pathogenesis demonstrate that many different recurrent genomic
J Oncol Pharm Pract 2020 Jan 21. [Epub ahead of print]. /
Background: As live expectancy and cancer incidence growing, polypharmacy in oncology patients is also increasing, raising the risk of developing potential drug–drug interactions.
Objective: To assess the prevalence of clinically relevant potential drug–drug interactions among cancer patients who receive parenteral treatment at our outpatient clinic. Method Retrospective observational study which included randomly selected
Int J Clin Pharm2019 ;41(6):1429-1433. /
Castro-Manzanares M, do Pazo-Oubiña F, Rodríguez-Rincón RM.
Importance: Chimeric antigen receptor (CAR) T-cell therapies are currently administered at a limited number of cancer centers and are primarily delivered in an inpatient setting. However, variations in total costs associated with these therapies remain unknown.
Objective: To estimate the economic differences in the administration of CAR T-cell therapy by the
JAMA Netw Open 2020;3(4):e202072. /
Lyman GH, Nguyen A, Snyder S, et al.
Background: Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse.
Methods: We here report the
The recent clinical successes of immunotherapy, as a result of a broader and more profound understanding of cancer immunobiology, and the leverage of this knowledge to effectively eradicate malignant cells, has revolutionised the field of cancer therapeutics.
Immunotherapy is now considered the fifth pillar of cancer care, alongside surgery, chemotherapy, radiotherapy, and
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single
Blood Adv. 2020;4(4):629-637. /
Maziarz RT, Waller EK, Jaeger U, et al.
Background: Medication discrepancies are a common occurrence following hospital admission and carry the potential for causing harm. However, little is known about the prevalence and potential risk factors involved in medication discrepancies in China.
Objective: To determine the frequency of medication discrepancies and the associated risk factors and evaluate the potential harmsof errors
Int J Clin Pharm 2020 Mar 27. [Epub ahead of print]. /
Guo H, Song J, Yin D,et al.